Waters Corporation (NYSE:WAT) Receives Average Rating of "Moderate Buy" from Analysts
Waters Corporation (NYSE:WAT) has received a consensus "Moderate Buy" rating from twenty analysts, with an average 12-month price target of $390.44. The company recently exceeded quarterly earnings estimates and issued strong FY2026 guidance. Insider trading shows Director Wei Jiang increased his stake by purchasing 500 shares, bringing insider ownership to 0.63% and institutional ownership to 94.01%.
Evercore ISI upgrades Waters stock rating on achievable targets
Evercore ISI has upgraded Waters Corp. (NYSE:WAT) stock rating to Outperform from In Line, setting a price target of $350.00, citing confidence in the company's first-quarter numbers and a favorable second-half turnaround. This upgrade comes despite some analyst concerns regarding the stock's valuation and recent acquisitions. The company trades at $304.24 with a market cap of $29.85 billion.
Thermo Fisher Microscopes: Precision in Scientific Imaging
This article details how Thermo Fisher microscopes are crucial for scientific imaging across various research and industrial applications. It highlights their advanced optical and electron models, cutting-edge features like high-resolution optics, fluorescence capabilities, and automation. The article also discusses their market relevance, competitive landscape, ongoing innovations, and significant impact on global health and scientific discovery.
Illumina (Nasdaq:ILMN) - Stock Analysis
This Simply Wall St report provides an in-depth stock analysis of Illumina (Nasdaq:ILMN), evaluating its valuation, future growth, past performance, financial health, dividends, management, and ownership. The analysis highlights that Illumina is trading below its estimated fair value, with earnings projected to grow, and the company recently became profitable. Various analyst narratives present differing views on the company's future, focusing on clinical genomics expansion, competitive challenges, and strategic product advancements.
WAT Financials: Revenue Breakdown, Margins & Competitor Comparison
Waters Corp (WAT) generates its revenue primarily through Waters Instrument Systems, which accounts for 35.2% of its total sales. The company demonstrates strong profitability with a gross margin of 59.79%, an operating margin of 29.01%, and a net margin of 24.16%. WAT competes with industry leaders like ALC and A, holding a significant market capitalization of $29.85B and maintaining competitive margins within the Advanced Medical Equipment & Technology sector.
Waters Corporation (WAT) stock price, news, quote and history
This article provides a detailed financial overview of Waters Corporation (WAT), covering its stock performance, key financial metrics, and company profile. It includes recent news, analyst insights, and comparisons with similar companies in the Diagnostics & Research industry, showing WAT's market position and operational scope.
Revvity, Inc. (RVTY) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.
Lab chromatographs are getting smarter: what Agilent is quietly changing for US labs
This article discusses how Agilent Technologies Inc. and other manufacturers are transforming US labs with smarter, more automated chromatographs. These new systems enhance throughput, compliance, and uptime through automation, AI-assisted analytics, and improved data integrity, moving beyond raw performance to focus on system-level intelligence and workflow efficiency. The piece highlights the benefits for labs struggling with staffing and regulatory burdens, positioning upgrades as a workflow redesign rather than just an instrument purchase.
Waters Corp (WAT) director gets deferred stock units grant
Waters Corp director Jiang Wei was granted 64.06 common stock units as part of the company's 1996 Non-Employee Director Deferred Compensation Plan, in lieu of cash director fees. These units, which convert to shares on a one-for-one basis, are scheduled for distribution on January 1, 2036. Following this grant, Jiang Wei directly holds a total of 3,505.33 common stock units/shares-equivalent.
Waters Corp (MIL:1WAT) Bonds
This page on GuruFocus provides an overview of Waters Corp (MIL:1WAT) bonds, including key financial metrics like P/E ratio, P/B ratio, market cap, and enterprise value. It also indicates that GuruFocus has detected two severe warning signs for the company. The page serves as a gateway to more detailed financial data, valuation forecasts, and other analytical tools available on the GuruFocus platform.
Waters Corp. stock outperforms competitors on strong trading day
Waters Corp. (WAT) stock saw a 1.45% increase, reaching $304.24 on Thursday. This performance outpaced the broader market, which experienced a mixed trading session with the S&P 500 Index rising 0.11% and the Dow Jones Industrial Average falling 0.13%. This marks the fourth consecutive day of gains for Waters Corp.
Parkman Healthcare Partners LLC's Waters Corp(WAT) Holding History
This article details Parkman Healthcare Partners LLC's historical holdings in Waters Corp (WAT), showing they hold 41,899 shares valued at $15.91 million, comprising 1.51% of their portfolio. It also provides a chart of quarterly buys and sells, and lists recent news articles related to Waters Corp. The information is presented within the GuruFocus platform context.
Key Factors and Emerging Trends Shaping the Lab Supplies Market Landscape
The lab supplies market is set to reach $60.9 billion by 2030, growing at an 8.5% CAGR, driven by advancements in life sciences, diagnostics, and automation. Key trends include increased demand for premium consumables, automated equipment, and a focus on safety and sustainability. Leading companies like Thermo Fisher Scientific and Danaher Corporation are innovating to enhance accuracy and efficiency, with acquisitions like Calibre Scientific's purchase of Dynalab Corp. expanding market reach and product portfolios.
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) has transformed into a "pure-play" medical technology entity after spinning off its Biosciences and Diagnostic Solutions unit and merging it with Waters Corporation. The company is now focused on medical delivery, interventional surgery, and connected care, aiming for high-margin software and automated systems. Despite past stock volatility and underperformance, BD’s financial profile shows strength, and it is positioned for growth through its focus on "Smart Connected Care" and addressing healthcare labor shortages and the aging population.
Key Factors and Emerging Trends Shaping the Life Science and Chemical Instrumentation Market Landscape
The life science and chemical instrumentation market is projected to reach $90.58 billion by 2030, driven by advanced omics technologies, personalized medicine research, and digital laboratories. Key trends include automated analytical instruments, high-throughput testing, and enhanced integration of laboratory information management systems, with major players like Agilent Technologies and Thermo Fisher Scientific leading innovation. Recent acquisitions, such as Spectris acquiring Micromeritics, highlight strategic moves to expand portfolios and leverage specialized expertise in this rapidly evolving sector.
Goldman Sachs Reinstates Buy Rating on Waters (WAT) Stock
Goldman Sachs has reinstated a Buy rating for Waters (WAT) stock with a target price of $375, indicating a potential 26% upside. The firm views a recent share price decline as a buying opportunity, citing challenges in the Biosciences and Diagnostic division as mostly one-time events. Waters Corp shows strong financial health with a robust Altman Z-Score and positive valuation metrics, despite inherent sector-specific risks.
Thermo Fisher’s Glacios 3 Cryo TEM Puts AI At Center Of Growth
Thermo Fisher Scientific recently unveiled its Glacios 3 Cryo-TEM, an advanced cryo electron microscope incorporating AI-supported tools and improved imaging clarity. This new system is designed to accelerate drug discovery and structural studies by reducing practical barriers to adoption. For investors, the launch represents a significant product milestone for the company, highlighting its focus on high-impact analytical tools and AI in drug development.
Waters Corp (WAT) Expands After BD Diagnostic Solutions Acquisition
Waters Corporation (WAT) is actively integrating its acquisition of BD Diagnostic Solutions and focusing on development ambitions, as discussed at the TD Cowen 46th Annual Health Care Conference. The company forecasts 6.25% organic growth in its core business for 2026, driven by strong performance in chemistry and services, though it anticipates some near-term headwinds in China. Waters plans to boost EPS growth and margin expansion through cost management and tariffs, while heavily investing in bioseparations.
Waters Corp. stock rises Tuesday, still underperforms market
Waters Corp. (WAT) stock saw a 1.51% increase on Tuesday, closing at $297.80. Despite this gain, the stock underperformed the broader market, as both the S&P 500 and Dow Jones Industrial Average experienced significantly larger percentage increases. This marks the second consecutive day of gains for Waters Corp. shares.
Waters Corp (WAT) Trading Down 3.79% on Mar 30
Waters Corp (WAT) shares dropped 3.79% in mid-day trading on March 30, reaching an intraday low of $288.45 before a slight recovery. This places the stock significantly below its 52-week high but still above its 52-week low. Analysts provide an average price target of $398.64, suggesting a substantial upside, and GuruFocus estimates a fair value of $717.92.
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why
Qiagen (QGEN) recently released new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test, showing improved tuberculosis detection and reduced healthcare costs. This strengthens the investment case by enhancing the product's clinical and economic credibility. While this supports Qiagen's long-term potential, the company's immediate focus remains on factors like QIAstat-Dx uptake and macroeconomic pressures affecting margins.
10 Recent Spin-off Companies That Hedge Funds Are Piling Into
This article highlights recent spin-off companies that are attracting significant hedge fund investment. Specifically, it focuses on Everus Construction Group Inc. (NYSE: ECG), detailing its recent financial performance and analyst upgrades. The company exceeded earnings and revenue forecasts, reported a record backlog, and received boosted price targets from Freedom Capital Markets and Cantor Fitzgerald due to strong end-market conditions.
Agilent Technologies' Advanced Chromatography Solutions: Driving Precision Analytics in North Americ
Agilent Technologies' chromatography solutions are essential for precision analytics in North American labs, especially with the rise of AI-driven research. Their GC and LC systems offer high accuracy for pharmaceutical, biotech, and environmental testing, positioning Agilent as a key player in the growing lab technology market. The company's innovations, market applications across diverse sectors, and strategic integration with AI platforms underscore its strong competitive position and growth prospects for investors.
Agilent Technologies' Advanced Chromatography Solutions: Driving Precision Analytics in North Americ
Agilent Technologies is positioned as a key player in analytical science, particularly in chromatography, with its GC and LC systems being essential for pharmaceutical, biotech, and environmental testing. The article highlights how Agilent's precision instruments are crucial for AI-driven research, enabling high-quality data for machine learning models and accelerating drug discovery and materials analysis. For investors, Agilent offers a stable investment in the growing lab tech market, bolstered by its technological superiority, diverse market applications, and strong financial performance.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several medical and research equipment company stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines in the afternoon trading session. This drop was attributed to investor uncertainty stemming from the U.S.-Iran conflict and upcoming policy deadlines, negatively impacting major indices like the S&P 500 and Dow Jones. Waters Corporation, in particular, saw its shares trade down, despite a previous significant merger announcement, with its stock currently 29.6% below its 52-week high.
Waters Corp (LTS:0LTI) Bonds
This GuruFocus page provides financial data and a summary for Waters Corp (LTS:0LTI) Bonds, including its stock price, market capitalization, P/E, and P/B ratios. It also highlights that GuruFocus has detected two severe warning signs for the company. The page encourages users to sign up for a free trial to access more detailed information and warnings.
Waters Corp. stock underperforms Friday when compared to competitors
Waters Corp. (WAT) shares fell by 3.79% to $289.16 on Friday, underperforming the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average experienced significant declines. This marks the second consecutive day of losses for Waters Corp. stock.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne stocks trade down, what you need to know
This article reports on several medical technology and life sciences companies whose stocks traded down. The companies mentioned are CONMED (CNMD), Bruker (BRKR), Waters Corporation (WAT), Avantor (AVTR), and Bio-Techne (TECH). The article does not provide specific reasons for the stock declines but indicates that investors may want to investigate further.
Vanguard disaggregates holdings; Waters Corp shows 0% stake (WAT)
Vanguard Group has filed an Amendment No. 16 to Schedule 13G/A, reporting 0% beneficial ownership and 0 shares in Waters Corp (WAT). This change is attributed to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, referencing SEC Release No. 34-39538. The filing indicates a disaggregation of reporting rather than a sale of shares.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines as major indices fell due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines. The market's reaction, amplified by concerns of prolonged conflict and rising oil prices, was reflected in a decline in consumer confidence. Despite the widespread dip, the article suggests that significant price drops can create opportunities to acquire high-quality stocks.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several prominent stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines in the afternoon trading session. This downtrend is attributed to investor reactions to escalating uncertainty from the U.S.-Iran conflict and policy deadlines, which led to a sharp fall in major indices like the S&P 500 and Dow Jones Industrial Average. The article highlights that such market overreactions can present buying opportunities for high-quality stocks.
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To Know
Several medical and research technology stocks, including CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne, experienced declines after major indices fell due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines. The market reacted negatively to unpredictability and rising oil price concerns, leading to a dip in consumer confidence. While these individual stock drops are significant, the article suggests that such downturns can present buying opportunities for high-quality stocks.
Agilent Technologies Inc. stock: Precision instruments leader navigating life sciences and diagnosti
Agilent Technologies Inc. is a leader in precision instrumentation for life sciences, diagnostics, and applied chemical markets, providing critical tools for pharmaceuticals, biotech, and environmental testing. The company's business model is diversified across three primary segments, focusing on innovation, global expansion, and a strong competitive moat. It offers North American investors exposure to high-growth areas within healthcare, balanced by recurring revenues and a commitment to capital returns.
Agilent Technologies Inc. stock climbs on launch of advanced chromatography solutions boosting life sciences research
Agilent Technologies Inc. stock has risen following the launch of new chromatography solutions designed to accelerate life sciences research and drug discovery. The innovations, which integrate enhanced separation technologies with AI-driven data processing, address key bottlenecks in biopharmaceutical development and are expected to expand Agilent's market share. This development aligns with renewed investor interest in life sciences tools and the ongoing recovery in biotech funding.
Waters Corp Stock: Analytical Instruments Leader Faces Growth Challenges Amid Sector Tailwinds
Waters Corp (NYSE:WAT) is a leader in analytical workflow solutions, providing instruments for lab research and quality control. While the company benefits from strong demand in sectors like biopharma and environmental testing and holds a strong market position, it faces challenges such as decelerating organic growth and margin pressure. Investors are monitoring its response to these issues and its potential for upside.
Waters Corp Stock: Analytical Instruments Leader Faces Growth Challenges Amid Sector Tailwinds
Waters Corp (NYSE:WAT), a leader in analytical workflow solutions, faces growth challenges despite tailwinds in the scientific instruments sector. The company specializes in liquid chromatography and mass spectrometry, serving pharmaceutical, biotech, and environmental testing markets. While institutional investors like Vanguard maintain positions, recent performance has been mixed, with modest share declines and analyst ratings leaning towards a "Moderate Buy."
Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus
Qiagen N.V. (ISIN: NL0012169213) is highlighted as a leading molecular diagnostics and life sciences tools company, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The article details its business model, core operations emphasizing recurring revenue from consumables, and strong market position in areas like next-generation sequencing and point-of-care testing. It also addresses the company's relevance for North American investors, competitive advantages, and potential risks, positioning it as a key player for long-term focus.
Agilent Technologies Inc. stock climbs on launch of advanced chromatography solutions boosting life sciences research
Agilent Technologies Inc. (US00846U1016) stock has risen following the launch of new chromatography solutions designed to accelerate life sciences research and drug discovery. The company's innovations address key challenges in biotechnology R&D, positioning Agilent as a leader in analytical instrumentation and attracting investor interest. This development comes amid renewed investor appetite for life sciences enablers and aims to expand Agilent's market share in high-growth areas.
Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom
Revvity Inc. is facing pressure due to a slowdown in the life sciences sector, marked by reduced research funding and biopharma spending cuts, which led to flat Q4 revenue and organic declines. US investors should monitor the upcoming Q4 results for insights into NIH funding impacts, biopharma R&D recovery, and the integration of acquisitions like BioLegend, especially given the company's significant US customer base and the resilience of its diagnostics segment. Despite sector headwinds, the company's services business provides stability, while its valuation and strategic acquisitions offer potential upside for growth-seeking investors.
Agilent Technologies Inc. stock climbs amid new chromatography solutions launch signaling life sciences expansion
Agilent Technologies Inc. (NYSE: A) stock rose after the company launched new chromatography solutions, enhancing its offerings for the life sciences sector. These advanced tools, designed for complex biomolecule analysis, are expected to accelerate drug discovery and boost Agilent's market share in biopharma and diagnostics. The move aligns with growing demand for precise analytical instruments and is seen as a strategic push into high-growth markets, attracting investor confidence.
Waters (MIL:1WAT) NonCurrent Deferred Revenue : €0 Mil (As of Dec. 2025)
This article reports that Waters (MIL:1WAT) has a NonCurrent Deferred Revenue of €0 Million as of December 2025. GuruFocus rates Waters with a GF Score of 26/100 and considers the stock significantly undervalued with a GF Value of €367.42 against a current price of €258.70. The report also highlights 2 warning signs for investors to review and provides historical data and comparative analysis for the company's non-current deferred revenue.
Waters (NYSE:WAT) Given New $330.00 Price Target at Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft has lowered its price target for Waters (NYSE:WAT) from $370.00 to $330.00, while maintaining a "hold" rating, suggesting a 9.3% upside. Other analysts have a more optimistic outlook, with an average price target of $394.63 and a "Moderate Buy" consensus rating for the medical instruments supplier. Waters recently surpassed quarterly earnings and revenue estimates and provided positive FY2026 guidance, yet several firms have adjusted their ratings and price targets on the stock.
Rep. Thomas H. Kean, Jr. Sells Alphabet Inc. (NASDAQ:GOOGL) Stock
Representative Thomas H. Kean, Jr. (R-NJ) recently sold Alphabet (GOOGL) shares from his "KEAN FAMILY PARTNERSHIP" on February 5th, with proceeds between $15,001 and $50,000. Alphabet, which recently reported strong earnings and a quarterly dividend, maintains a consensus analyst rating of "Moderate Buy" with a target price of $367.18. The article also details other recent trades by Representative Kean Jr., institutional activity in Alphabet stock, and key news influencing the company.
Agilent Technologies Inc. stock rises on advanced chromatography solutions launch boosting life scie
Agilent Technologies Inc. (A) has launched advanced chromatography solutions aimed at improving lab efficiency in pharmaceutical research and quality control. This move comes amidst surging biotech investments and heightened demand in the pharma and biotech sectors, positioning Agilent for sustained revenue growth. The stock is trading around $111 on the NYSE, reflecting investor confidence in the company's innovation and its strategic fit within the booming life sciences market.
Waters (NYSE: WAT) subsidiary sells $3.5B in new senior notes
Waters Corporation's subsidiary, Augusta SpinCo Corporation, successfully completed a $3.5 billion public offering of senior unsecured notes across five tranches. These notes, maturing between 2027 and 2036 with coupon rates from 4.321% to 5.245%, are fully guaranteed by Waters Corporation. The company plans to use the net proceeds, along with cash on hand, to repay an existing $3.5 billion delayed draw term loan, effectively refinancing its debt with longer-term bonds.
Waters (WAT) Prices $3.5 Billion Senior Notes Offering
Waters Corporation (NYSE: WAT) has announced the pricing of a $3.5 billion senior notes offering through its subsidiary, Augusta SpinCo Corporation, with maturities from 2027 to 2036 and interest rates between 4.321% and 5.245%. The proceeds will be used to repay existing debts. Additionally, Waters launched ARES-G3™ Rheometer, a new instrument that significantly improves data capture and reduces testing times in life sciences diagnostics.
US Multiomic Market Set to Boom Rapidly, Witnessing Strong
Coherent Market Insights has released a new research study on the Global "US Multiomic Market" forecasting strong growth through 2033. The report segments the market by type (Genomics, Proteomics, Metabolomics) and applications (Precision Medicine, Drug Discovery, Clinical Research), and provides competitive and regional analysis. Key players include Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc.
Waters Raises $3.5 Billion in Senior Notes to Refinance February Term Loan
Waters, through its subsidiary Augusta SpinCo, has completed a $3.5 billion public offering of senior notes across five tranches due between 2027 and 2036. The company intends to use these proceeds, along with cash on hand, to repay an outstanding $3.5 billion delayed draw term loan incurred in February 2026. The notes are guaranteed by Waters and certain subsidiaries and are governed by an indenture with U.S. Bank Trust Company.
3 Medical Device Companies Leveraging GenAI to Address Industry Challenges
This article examines the growing role of Generative AI (GenAI) in the medical instruments sector, highlighting its impact on diagnostics, patient monitoring, and clinical workflows. It reviews the industry's outlook, performance, key trends like GenAI transformation and M&A, and spotlights three companies—Globus Medical (GMED), Tactile Systems Technology (TCMD), and IRadimed Corp. (IRMD)—that are leveraging GenAI and strategic moves to address market demands. The article also provides financial metrics and projections for these companies, suggesting their potential as promising investments.
Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit
This article reports that Waters Corporation (WAT) stock is declining due to discussions regarding a potential combination with a Becton Dickinson unit. The news suggests a significant strategic move for Waters, potentially impacting its market valuation and future operations. Investors are reacting negatively to the prospect of this deal.
